Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer

To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC

Inclusion Criteria:

• histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)
• no prior chemotherapy
• WHO criteria for disease status assessment

Exclusion Criteria:

• Concurrent administration of any other tumor therapy
• pregnant or breast feeding
• serious concomitant disorders